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OBJECTIVE: The Neonatal Adverse Event Severity Scale (NAESS) was developed to improve scoring of neonatal adverse events
(AEs) and accelerate neonatal drug development. This is the ﬁrst validation study of the novel tool.
STUDY DESIGN: Retrospective validation study assessing the inter-rater reliability (IRR) of the NAESS. Reviewers used real-world AE
data from a neonatal trial. Intra-class correlation (ICC) statistical analysis was performed.
RESULT: Sixty AEs were randomly assigned to twelve reviewers for a total of 240 severity scores. Generic and AE-speciﬁc NAESS
tables were assessed. The ICC was 0.63 (95% conﬁdence interval 0.51 to 0.73). Percent variation due to reviewer and residual error
was 0.03 and 0.34, respectively.
CONCLUSION: In this ﬁrst study of the NAESS tool, an ICC of 0.63 indicates moderate reliability. Results highlight the need for
improved data collection on neonatal AE forms, augmented training on the NAESS tool, and will inform the prospective validation
studies.
Journal of Perinatology (2021) 41:2813–2819; https://doi.org/10.1038/s41372-021-01164-w

INTRODUCTION
Adverse event (AE) severity scoring is an essential component of
all therapeutic intervention trials. An AE is deﬁned by the Food
and Drug Administration (FDA) as “any untoward medical
occurrence associated with the use of a drug in humans, whether
or not considered drug related.” AE scoring typically involves
assigning a severity grade between 1 (mild) and 5 (death). Events
are additionally classiﬁed as serious (SAE) if they result in: inpatient
hospitalization, prolongation of hospital course, a life-threatening
occurrence, or death.
The recognition and classiﬁcation of AEs is challenging in
neonates, particularly those receiving intensive care who are most
likely to be involved in clinical trials. Hospitalized neonates can have
very complex physiology with multi-organ system dysfunction and
many AEs. The unique types of neonatal AEs do not mirror the
symptom classiﬁcation in adults and children. Until recently, there
were multiple tools used to assess AE severity in adults and children
[1, 2], but none were developed and validated speciﬁcally for
neonates. Additionally, each pharmaceutical company and clinical
research organization use their own approach and interpretation of
neonatal AEs, making safety results from different studies difﬁcult to
compare. To study and ensure safety of a drug in neonates,
investigators need a tool for improvement and standardization of
neonatal AE collection and severity classiﬁcation.
In 2019, the Neonatal AE Severity Scale (NAESS V.1.0) was
published and the tool was placed on-line (https://evs.nci.nih.gov/
ftp1/INC/Adverse_Events_Terminology/) [3]. This tool was created

using a stepwise consensus approach and multiple rounds of
revision based on the Delphi approach among diverse stakeholders including physicians, nurses, academic researchers, as well
as industry representatives. The NAESS provides a generic table
and 35 multiple organ system and AE-speciﬁc tables. The NAESS
deﬁnes severity grade of AEs using suitable neonatal speciﬁc
severity markers, descriptions, and physiologic parameters. These
NAESS terms were linked to lowest level terms in MedDRA and
when possible, deﬁnitions for AEs were based on the NCI
thesaurus Pediatric AE terminology subset [1]. Age-appropriate
activity, basal physiology, and care changes are integral indicators
of neonatal AE severity in NAESS. While the International Neonatal
Consortium (INC) had multi-stakeholder engagement in the
creation of this new tool, validation testing using an independent
cohort of neonatal AEs was needed in order to examine the
performance of the tool in “real-world” situations.
The validation process requires a multi-step procedure to assure
internal validity and generalizability. The main goal of a tool for
standardization is to reduce interobserver variability. Evaluation of
the ability of the tool to improve interobserver agreement is thus a
critical aspect of validation. This retrospective study uses real
neonatal AE data collected as part of a recently published
randomized, controlled trial involving intratracheal administration
of a recombinant human club cell (CC10) protein in premature
neonates to prevent respiratory morbidity [4]. This approach
provided the ﬁrst step in validation of the NAESS tool by assessing
the inter-rater reliability of AE scoring.
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Fig. 1 Tables from the Neonatal Adverse Event Severity Scale. Example of a generic and b AE-speciﬁc table. The AE-speciﬁc table displayed
is for Apnea.

METHODS
This retrospective validation study was designed to evaluate inter-rater
reliability using the intra-class correlation (ICC) as the statistical test among
AE severity scores obtained from different reviewers using the NAESS
scoring tool. The study involved 12 independent reviewers and 60
previously reported AEs (referred to as “cases”; 35 SAE and 25 AEs),
collected as part of the previously described neonatal clinical trial [4]. Each
reviewer assigned severity scores for 20 cases with each case reviewed by
four reviewers. This study was submitted to the Children’s Mercy Hospital
IRB and was deemed exempt on 3 December 2019. While the study was
deemed exempt from IRB review, the invitation to the reviewers included a
clear acknowledgment of the following items: (1) the project was identiﬁed
as research, (2) participation was voluntary, (3) beneﬁts and risks to
reviewers were disclosed and (4) contact information of the PI was
provided.

Adverse event data

The case data used to assess inter-rater reliability were electronic ﬁles of
the actual AE forms collected during the following clinical trial [4]. This
study assessed the safety and efﬁcacy of a single intratracheal dose of
rhCC10 delivered in the ﬁrst 24 h after premature birth in reducing chronic
pulmonary insufﬁciency of prematurity at 12 months of life. Eighty-eight
infants (gestational age 24–29 weeks, birth weight 600–1200 g) were

randomized at six study sites. AEs were recorded on standard paper case
report forms, identifying information was redacted, and the information
was provided to the reviewers. The clinical trial data included a total of 190
cases that were originally reported to be either serious (SAE, N = 162) or
non-serious (AE, N = 28). To select the 60 most representative cases, we a
priori chose to identify 35 SAEs and 25 AEs to represent the NAESS
spectrum of grades 1–5. Thirty cases were highlighted using disease
speciﬁc NAESS tables and 30 cases using the generic NAESS table (Fig. 1).
The research team used the following case inclusion criteria: (1) the case
occurred during the initial birth hospitalization and before the neonate
reached a post-menstrual age of 44 weeks; (2) no more than one SAE and
one AE was used from each individual neonate; (3) cases were selected to
represent physiologic abnormalities covering multiple organ systems and
representative of common pathologies in preterm neonates; (4) AE case
report form handwriting was legible. Only one death was included among
the cases for the validation as it was assumed that there would be no
disagreement among reviewers in assigning the correct grade (grade = 5
for a death). We also wanted to focus on the reliability of the NAESS when
applied to cases that are more challenging to grade.

Case reviewers
Twelve independent AE reviewers were asked to assign severity scores for
the cases. The study team solicited interested participants from among
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Table 1.

List of NAESS tables used by reviewers to deﬁne severity to cases.

Name of NAESS scoring table

Serious adverse event

AEs category as deﬁned by original RCT

35

25

Generic NAESS tablea

9

12

Adverse event

Infectious—Neonatal Culture Positive Sepsis

5

0

Neurological—Neonatal Intraventricular Hemorrhage (IVH)

3

3

Respiratory—Infantile Apnea

2

3

Infectious—Neonatal Culture Negative Sepsis

2

1

Neurological—Retinopathy of Prematurity (ROP)

2

1

Respiratory—Neonatal Respiratory Insufﬁciency

2

1

Gastro-intestinal—Neonatal Gastrointestinal Bleeding

2

0
1

Gastro-intestinal—Feeding Intolerance

1

Respiratory—Neonatal Pulmonary Hemorrhage

1

1

Cardiovascular—Neonatal Coagulation Disorder

1

0

Cardiovascular—Neonatal Edema

1

0

Cardiovascular—Neonatal Tachyarrhythmia

1

0

Gastro-intestinal—Neonatal Spontaneous Intestinal Perforation (SIP)

1

0

Gastro-intestinal— Necrotizing Enterocolitis (NEC)

1

1

Respiratory—Neonatal Pneumothorax

1

0

Cardiovascular—Neonatal Hypotension

0

1

Gastro-intestinal—Necrotizing Enterocolitis (NEC)

0

1

a

Cases where the generic table was used included PDA, pneumonia, UTI, feeding intolerance, hepatic bleeding, conjunctivitis, inguinal hernia, anemia,
thrombocytopenia, hyperbilirubinemia.
The AE-speciﬁc tables are listed in descending order by frequency of use.

members of INC. We excluded participants who were directly involved in
the development of the original NAESS tool. Among interested participants,
12 reviewers were chosen who had previous experience with neonatal
clinical trials and represented different neonatal clinical trial stakeholders
(academia, regulators, industry). The case assignment randomization was
stratiﬁed by whether the case was deemed in the original clinical trial to be
an SAE versus AE, whether there existed a speciﬁc NAESS table
corresponding to it, or whether the generic table was required.
Each reviewer received a standard zip ﬁle by email that included the
NAESS tool (including the generic table and the 35 published AE speciﬁc
tables), 20 individual de-identiﬁed case-report forms for the speciﬁc case;
and an excel ﬁle for recording demographic data pertaining to their trial
experience and the severity score (#1–5) that was assigned. The predeﬁned severity assessment from the original RCT was masked in the ﬁle
naming. The reviewer was blinded as to whether the case was deemed an
SAE or AE in the original RCT, but the ﬁle name did specify “0” for generic
table use and “1” for speciﬁc table use.

Sample size and statistical analysis
A sample size of 60 cases with 4 independent reviews per case was
projected to result in a 95% conﬁdence interval for the intra-class
correlation coefﬁcient (ICC) of width 0.28, 0.26, 0.19, or 0.08 if the true ICC
were 0.3, 0.5, 0.7, or 0.9, respectively. Data were analyzed using a linear
mixed effects model ﬁt by restricted maximum likelihood with random
effects for case and reviewer. The percent of variation attributable to case,
reviewer, and error were calculated from the model. The ICC is the percent
of variation attributable to the case and is used as a measure of inter-rater
reliability. Analyses were repeated, subgrouping the cases by serious
versus non-serious status and whether all reviewers used matching NAESS
tables. R version 3.6.0 and packages lme4 and irr were used for calculations
http://www.R-project.org/ [5, 6].

RESULTS
This study explored AE severity scores among a broad range of
adverse clinical trial events, both SAEs and AEs, utilizing diseasespeciﬁc and generic tables found in the NAESS scoring tool
(Table 1). Reviewer’s neonatal clinical trial experience is depicted
Journal of Perinatology (2021) 41:2813 – 2819

in Table 2. The reviewers were mostly from academia and
government including principal investigators, research coordinators, a data safety monitoring board member, and a regulator
(Table 2).
As a result of the randomization, each of the 12 reviewers
received 10 events that could be scored using a disease-speciﬁc
NAESS table (3 AEs and 7 SAEs) and 10 events that could be
scored using a generic (non-disease oriented) NAESS table (4 or 5
AEs and 5 or 6 SAEs). The ﬁnal analysis data set contained severity
scores provided by 12 reviewers for 240 events (60 cases, each
reviewed 4 times).
The distribution of the 240 rater-assigned severity scores is seen
in Fig. 2. The intra-class correlation (ICC, the percent of total
variation due to the cases) was 0.63 (95% conﬁdence interval 0.51
to 0.73). The ICC is graphically displayed in Fig. 3. The percent
variation due to reviewer and residual error was 0.03 and 0.34,
respectively. The ICCs for the separate analyses of AEs and SAEs
were 0.72 (95% CI 0.56 to 0.85) and 0.55 (95% CI 0.39 to 0.71),
respectively. When all four raters used the exact same NAESS table
to score the AE, the ICC was 0.63 (95% CI 0.487 to 0.758) and when
the raters used at least one different table, the ICC was 0.558 (95%
CI 0.340 to 0.762). The distribution of the 240 scores can be seen in
Fig. 2.
Among the 60 cases, the severity scores that the reviewers
returned were completely concordant (same score from all four
reviewers) for 11 (18.3%) cases. There were two different severity
scores for 43 (71.7%) cases, and three different severity scores
assigned for 7 (11.7%) cases. Most case reviews used the disease
speciﬁc or generic NAESS tables based on the names of the prespeciﬁed tables in the tool. Among the 120 reviews of the 30 cases
that the study team had identiﬁed to have a matching prespeciﬁed AE-deﬁned NAESS table, the reviewers used the
predicted NAESS table in 107/120 (87%) of case reviews.
Reviewers unexpectedly chose to use the generic NAESS table in
12/120 (10%) of these cases and a different AE-speciﬁc table in 1
case review (coagulation disorder table used instead of
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Table 2.

Case reviewer demographics.
Role

Years*

Primary Job Area

Neonatal RCT with
any drug#

If yes, how many?

Country

Reviewer 1

Research Coordinator

20

All$

Yes

2

USA

Reviewer 2

Research Coordinator

5

Academia

Yes

3

USA

Reviewer 3

PI

4

Academia

Yes

4

Reviewer 4

PI

2

Academia

No

Reviewer 5

PI

16

Academia

Yes

5

USA

Reviewer 6

PI

15

Government

Yes

3

UK

Reviewer 7

PI

25

Government

Yes

25

UK

Reviewer 8

Data Safety Monitoring
Board member

3

Academia

Yes

12

USA

Reviewer 9

Regulatory Reviewer

3

Government

No

Reviewer 10

Regulatory Reviewer

19

Government

No

Reviewer 11

Research Coordinator

12

Academia

Yes

Reviewer 12

Regulatory Reviewer

20

Academia

No

Summary statistics
(median, IQR)

(12, 14)

USA
USA

Canada
USA
3

USA
Japan

(3.5, 3.75)

$

We believe this response indicates that the reviewer has held jobs in academia and industry.
Number of years in their current job position.
#
Involvement with neonatal RCT involving a drug within the past three years.
*

intraventricular hemorrhage table). Among the 120 reviews of the
30 cases requiring use of the generic NAESS table, 110/120 (92%)
used the generic table. However, 10/120 (8%) reviews were
performed using an AE-speciﬁc NAESS table. An example of this is
a reviewer who used the “respiratory insufﬁciency” table for
review of an AE related to a patent ductus arteriosus (PDA).
Among the 12 reviewers, 10 used a different table than
expected at least once. Six reviewers failed to use a corresponding
disease-speciﬁc table at least once, and ﬁve reviewers used an AEspeciﬁc table when they should have used the generic table, at
least once. Much of the discrepancy in NAESS table usage came
from cases of pneumonia, tracheitis, and urinary tract infections.
These cases do not have a pre-deﬁned AE-speciﬁc NAESS table, so
the study team had predicted use of the generic NAESS table.
Instead, the reviewers chose to use either the “culture positive
sepsis” or “culture negative sepsis” tables in the tool. Additionally,
there was no AE-speciﬁc table for PDA in the current tool and
some PDA cases were scored using AE-speciﬁc tables for
“respiratory insufﬁciency” or “edema”.
DISCUSSION
This is the ﬁrst study to evaluate the validity of the NAESS tool,
demonstrating an intra-class correlation (ICC) of 0.63 which
indicates moderate reliability [7]. The variation due to individual
reviewers was very small, so there was no appreciable reviewer
bias such as a tendency to grade high or low. The limitation of the
NAESS tool, as used in this study, is due to other sources of
variation or error including lack of detailed explanation of events
on the AE case report forms, variation in use of Generic versus
Speciﬁc NAESS Tables, and a study design where deaths were not
routinely included. Additionally, unlike real-time AE severity
grading, reviewers did not have access to the clinical team who
cared for the neonates with information limited to data on case
report forms.
The ICC of 0.63 is similar to that observed in other studies of AE
reporting. A study of oncologists rating adverse symptom events
in cancer patients demonstrated an ICC ranging from 0.46 for
vomiting to 0.71 for neuropathy [8]. The Spinal Adverse Events
Severity system (SAVES-V2) demonstrated an interobserver ICC of
0.75 in a retrospective study using clinical vignettes [9]. Our study

is unique in its use of actual case report forms from an RCT. Site
investigators and study coordinators with full access to neonates,
their electronic health record, and their care providers would likely
have resulted in a higher ICC. However, our study design using
true CRF data is consistent with AE review processes at the
sponsor, DSMB, and regulatory levels where information is limited
to data contained in case report forms. It is possible that the ICC
would be higher if a more homogeneous group of reviewers
(either by job title or years of experience) were used, but this
study was designed to assess the tool reliability in a diverse group
of individuals. We understand that various stakeholders will be
using this tool in neonatal drug development and purposefully
recruited the reviewer pool to reﬂect this.
This study highlights areas for improvement in AE case report
forms. Reviewers attributed difﬁculty in assigning a severity score
due to the limited information provided on these standard AE case
report forms. NAESS tables required reviewers to consider changes
in age appropriate behavior, basal physiology and the treatments
provided for events. Without such information, some variation in
scoring is not surprising. AE forms offer blank spaces to name and
describe the event often in a narrative format. Non-serious AE case
report forms typically offer limited one-line space for each event
such that multiple events are collected on a single page. This lack
of information and inconsistent narrative approach makes it
difﬁcult to assign severity, particularly in premature neonates in
whom the outcomes reﬂect multi-organ disease processes. The
NAESS severity grading criteria could be embedded into standard
case report forms so that site investigators would provide the
assessment of minor or major changes in baseline age-appropriate
behavior or basal physiologic processes. Case report forms could
also specify speciﬁc treatments required for patient stabilization.
For example, information about additional medications, procedures, or changes in respiratory support in response to the event
would aid in severity assessment. Current prospective validation
studies of the NAESS tool will permit reviewers to have access to
rich real-time clinical information when assigning the severity score
which should improve accuracy and reliability.
There were two ICC sub-analyses performed. In the ﬁrst analysis,
the ICC was higher for AEs compared to SAEs (0.72 vs 0.55). This
was an unexpected result because the SAE forms had much more
rich detailed information while the AE forms had minimal clinical
Journal of Perinatology (2021) 41:2813 – 2819
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Fig. 2 The frequency of severity scores assigned to cases. Panels a
all 60 cases, b cases deﬁned as AEs, and c cases deﬁned as SAEs.

details. Paradoxically, fewer details may actually have led to less
subjectivity in scoring the AE. More serious AEs may have been
harder to classify because of the complex information presented
which could lead to some uncertainty in the score by the case
reviewer. When all four raters used the exact same NAESS table to
score the AE (40 raters), the ICC was 0.63 and when the raters used
at least one different table, the ICC was 0.56. This implies that
different raters using varying tables for the same AE could
decrease the reliability of the tool and improving standard training
around the use of the tool could also improve reliability. The
NAESS tool is complex in that there is a generic table and multiple
AE-speciﬁc tables and it is not known if less complexity of the tool
would increase reliability. The AE-speciﬁc tables allow a lot more
relevant details for a speciﬁc AE to be considered in severity
scoring. In future studies, we plan to assess the trade-off of
simplicity (less tables) for speciﬁcity (multiple AE-speciﬁc tables).
Study design also likely contributed to lower ICC. If more than
one death had been included, the ICC would have been higher. In
addition, many reviewers chose to use a NAESS table other than
what had been recommended. If the study team had assigned
speciﬁc NAESS table for each case, perhaps the ICC would be
higher. This real-world exploration of the NAESS revealed
inconsistency over which NAESS table to use for speciﬁc types
Journal of Perinatology (2021) 41:2813 – 2819

of events. The varied use of Generic versus Speciﬁc NAESS tables
was an interesting and unexpected ﬁnding that highlights the
importance of this study in end-users who are naïve to the tool.
The study team chose to leave some autonomy to case reviewers
because we wanted the tool to be as “real-world” as possible
during this ﬁrst step of validation process. The NAESS tool could
be improved by providing more explicit instructions and training
on the tool and by the addition of even more event-speciﬁc tables.
Standard event terminology could help trigger the appropriate
NAESS tool and may also allow linkage between EHR and AE
reporting [1].
Reviewers preferred speciﬁc AE tables to the generic table even
when the event did not match an existing speciﬁc event table. For
example, for cases of infections (pneumonia, tracheitis) some
reviewers chose the speciﬁc table “culture negative sepsis” instead
of the generic table. In a case of hepatic hemorrhage, some
reviewers used the gastrointestinal bleeding Speciﬁc AE table
instead of the generic table. The NAESS does not yet include
speciﬁc tables for laboratory abnormalities. For a case of
thrombocytopenia, the reviewer used “coagulation disorder”
instead of the generic table. Although this ﬁrst iteration of the
NAESS tool contained 35 speciﬁc tables, it is now clear that more
speciﬁc tables are needed. Along with further infectious disease
related tables, a speciﬁc table for PDA and speciﬁc laboratory
abnormalities could immediately improve the tool.
The seven cases that returned the most variable severity scores
(three different severity grades among the reviewers) highlight
the need for improvement and standardization in AE data
collection and reporting. For these speciﬁc 7 cases, all reviewers
used the same NAESS tables. More education and understanding
about assessing basal physiology and using the NAESS may
improve consistency. These cases were likely to have insufﬁcient
data for the reviewer to make a conﬁdent severity assessment and
may reinforce the need to standardize the information collected
on AE case-report forms, speciﬁcally treatments provided and
changes in basal physiology. As discussed, there was greater
consistency in severity scores for AEs compared to SAEs.
This study has strengths and limitations. The strengths of the
study include the use of real case report forms from a recent
neonatal RCT [4]. This use of real AE data allowed us to test the
NAESS tool in a retrospective way that was internally validated. In
addition, the 12 reviewers were naïve to the tool itself, so this study
represented how the tool will perform in the hands of new users
from multiple stakeholder groups. Lastly, this validation study
captured a wide range of AE types and severity, allowing assessment
over the entire range of the tool. The major limitation to this study
was that the data collection was non-standardized and did not
contain detailed information. The reviewers received copies of the
case report forms, exactly the way the local study team
documented. The reviewers commented that the major limitation
of using the NAESS was the brevity of the information and
inconsistency of detail provided on the case-report forms. In this
way, this research study cannot purely assess rater performance
because the cases themselves add some variability to the severity
rating. This reinforces the need to standardize SAE/AE reporting and
continue to strengthen the tool for more wide-spread use. Revisions
in AE case report forms are needed to enhance data quality and
severity assessment. A prospective validation study might overcome
these limitations with the use of for purpose-designed case report
forms and real-time bedside clinical information.
In addition to creation of this new NAESS tool, the neonatal
clinical trial space needs a more standard and comprehensive way
to collect AE data. Ongoing efforts at standardization of
terminology and data harmonization [1, 10] will improve data
collection and may even allow the EHR to systematically capture
AEs. To facilitate this goal, the NAESS adverse event terminology is
publicly available on the NCI Thesaurus (https://ev.nci.nih.gov/
ftp1/INC/Adverse_Events_terminology) and terms have been

T. Lewis et al.

2818

Fig. 3 Intra-class correlation of the scores assigned to the 60 cases, each reviewed four times. The x-axis is each individual case. Perfect
inter-rater reliability is when all four reviewers scored the case the same. Blue dots represent serious adverse events and red dots are nonserious adverse events.

mapped to NICHD Pediatric AE terminology and MedDRA lowest
level terms. In the NICU, standardized minimum datasets have
been used to improve research efforts and quality improvement
with consensus groups having identiﬁed 12 critical outcomes for
all future trials involving neonates cared for in high-income
settings [11]. There is signiﬁcant overlap in these critical outcomes
and AEs, therefore uniform reporting of core-outcomes would also
improve AE reporting. Leveraging the EHR in automated datacapture provides another mechanism to standardize AE reporting,
with automated data capture from the EHR improved AE reporting
for bacterial infections in children with acute myeloid leukemia
[12]. With continued efforts to standardize terminology, data
elements, and core outcome measures, we can leverage the EHR
to improve AE reporting in neonates.
Improved processes of data collection and standardization of AE
reporting are critical to patient safety and advancing neonatal
therapeutics. The NAESS can be expanded to include more terms
and conditions and speciﬁc education efforts on the use of the
tool are being developed. Criteria for laboratory AEs are also
needed as neonatal reference ranges are different from those in
older patients. A prospective study using NAESS is ongoing, with
the addition of standard training of case reviewers to address
some of the limitations of this retrospective study.
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